How much funding has Alamar Bio raised?

Alamar Bio has raised $50.0M in total funding, most recently a Convertible Note round.

Who are Alamar Bio's investors?

Alamar Bio's investors include Illumina Ventures, Qiming VP, J.P. Morgan, BofA Securities, T. Rowe Price, Sands Capital.

When was Alamar Bio founded?

Alamar Bio was founded in 2018.

Where is Alamar Bio headquartered?

Alamar Bio is headquartered in Fremont, California, United States.

What industry is Alamar Bio in?

Alamar Bio operates in Biotech, Healthcare.

How many employees does Alamar Bio have?

Alamar Bio has 51-200 employees.

Alamar Bio

IPO

Powering Precision Proteomics.

Fremont, United States · Founded 2018 · $50.0M raised

Biotech

Healthcare

Headquarters: Fremont, California
Employees: 51–200
Founded: 2018
Business Model: B2B

Total Funding: $50.0M
Last Round: $50.0M Convertible Note
Rounds: 2

About

Alamar Biosciences (also known as Alamar Bio) is a precision proteomics life sciences company headquartered in Fremont, California, founded in 2018. The company's mission is to power precision proteomics to enable the earliest detection of disease. Alamar's core innovation, the NULISA technology platform, enables ultra-high sensitivity and high specificity analysis of hundreds of protein biomarkers from as little as 10 microliters of biofluid in a single sample. Products include the ARGO HT System and a growing portfolio of NULISAseq and NULISAqpcr assay panels spanning immunology, neurology, and oncology indications. The company filed for an IPO on Nasdaq in early 2026 targeting a $100M raise, having achieved $74M in revenue with 195% year-over-year growth.

Summary

Alamar Bio is a Biotech company based in Fremont, United States, founded in 2018. It has raised $50.0M in total across 2 rounds. Investors include Illumina Ventures, Qiming VP and J.P. Morgan.